Article in Archiv der Pharmazie, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
2 · The registry
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
5 · Who and what money
Authors and funding
9 authors.
Manoel Oliveira de Moraes JuniorNational Institute of Science and Technology of Pharmaceuticals and Medications (INCT-INOFAR), Federal University of Rio de Janeiro, Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), CCS, University City, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0001-6354-1064
Gisele BarbosaNational Institute of Science and Technology of Pharmaceuticals and Medications (INCT-INOFAR), Federal University of Rio de Janeiro, Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), CCS, University City, Rio de Janeiro, Brazil.
Caroline Marques Xavier da CostaNational Institute of Science and Technology of Pharmaceuticals and Medications (INCT-INOFAR), Federal University of Rio de Janeiro, Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), CCS, University City, Rio de Janeiro, Brazil.
Raysa Magali Pillpe-MezaNational Institute of Science and Technology of Pharmaceuticals and Medications (INCT-INOFAR), Federal University of Rio de Janeiro, Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), CCS, University City, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0002-5116-1539
Wesley Leandro de GouveiaNational Institute of Science and Technology of Pharmaceuticals and Medications (INCT-INOFAR), Federal University of Rio de Janeiro, Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), CCS, University City, Rio de Janeiro, Brazil.ORCID https://orcid.org/0009-0001-5269-2008
Daniel Nascimento do AmaralNational Institute of Science and Technology of Pharmaceuticals and Medications (INCT-INOFAR), Federal University of Rio de Janeiro, Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), CCS, University City, Rio de Janeiro, Brazil.
Luis Gabriel Valdivieso GelvesNational Institute of Science and Technology of Pharmaceuticals and Medications (INCT-INOFAR), Federal University of Rio de Janeiro, Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), CCS, University City, Rio de Janeiro, Brazil.ORCID https://orcid.org/0000-0002-6013-2879
Stefan LauferNational Institute of Science and Technology of Pharmaceuticals and Medications (INCT-INOFAR), Federal University of Rio de Janeiro, Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), CCS, University City, Rio de Janeiro, Brazil.
Lídia Moreira LimaNational Institute of Science and Technology of Pharmaceuticals and Medications (INCT-INOFAR), Federal University of Rio de Janeiro, Laboratory of Evaluation and Synthesis of Bioactive Substances (LASSBio), CCS, University City, Rio de Janeiro, Brazil.
Funding
This study was supported by Instituto Nacional de Ciência e Tecnologia de Fármacos e Medicamentos and Fundação Carlos Chagas Filho de Amparo à Pesquisa do Estado do Rio de Janeiro.
6 · The paper itself
Abstract
Due to the arising of clinically relevant resistant EGFR-related phenotype through innovative mechanisms, mainly EGFR
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.
Investigation on LASSBio-1971 and LASSBio-1974 Cellular Cytotoxic Mechanism and Their Comparative DMPK Profile. · full record | OpenQuestion